Journal of Biological Chemistry · 2002 · 43 citations · 42 references
Life SciencesMolecular BiologyPharmaceuticsDrug DeliveryGene DeliveryGene TherapyEndosomal EscapeLate EndosomesLysosomal DegradationLysosomal TraffickingLysosomal TransportLysosome BiologyCholesterol AccumulationCholesterol Content In LiposomesEndosomal RetentionLiposomesLysosomal Cargo DegradationLysosomal Degradation PathwaysLysosome PathwayTargeted Liposomes
The transfection ability of nonviral gene therapy vehicles is generally hampered by untimely lysosomal degradation of internalized DNA. In this study we describe the development of a targeted lysosome disruptive element to facilitate the escape of DNA from the lysosomal compartment, thus enhancing the transfection efficacy, in a cell-specific fashion. Two peptides (INF7 and JTS-1) were tested for their capacity to disrupt liposomes. In contrast to JTS-1, INF7 induced rapid cholesterol-independent leakage (EC50, 1.3 μm). INF7 was therefore selected for coupling to a high affinity ligand for the asialoglycoprotein receptor (ASGPr), K(GalNAc)2, to im- prove its uptake by parenchymal liver cells. Although the parent peptide disrupted both cholesterol-rich and -poor liposomes, the conjugate, INF7-K(GalNAc)2, only induced leakage of cholesterol-poor liposomes. Given that endosomal membranes of eukaryotic cells contain <5% cholesterol, this implies that the conjugate will display a higher selectivity toward endosomal membranes. Although both INF7 and INF7-K(GalNAc)2 were found to increase the transfection efficiency on polyplex-mediated gene transfer to parenchymal liver cells by 30-fold, only INF7-K(GalNAc)2appeared to do so in an ASGPr-specific manner. In mice, INF7-K(GalNAc)2 was specifically targeted to the liver, whereas INF7 was distributed evenly over various organs. In summary, we have prepared a nontoxic cell-specific lysosome disruptive element that improves gene delivery to parenchymal liver cells via the ASGPr. Its high cell specificity and preference to lyse intracellular membranes make this conjugate a promising lead in hepatocyte-specific drug/gene delivery protocols. The transfection ability of nonviral gene therapy vehicles is generally hampered by untimely lysosomal degradation of internalized DNA. In this study we describe the development of a targeted lysosome disruptive element to facilitate the escape of DNA from the lysosomal compartment, thus enhancing the transfection efficacy, in a cell-specific fashion. Two peptides (INF7 and JTS-1) were tested for their capacity to disrupt liposomes. In contrast to JTS-1, INF7 induced rapid cholesterol-independent leakage (EC50, 1.3 μm). INF7 was therefore selected for coupling to a high affinity ligand for the asialoglycoprotein receptor (ASGPr), K(GalNAc)2, to im- prove its uptake by parenchymal liver cells. Although the parent peptide disrupted both cholesterol-rich and -poor liposomes, the conjugate, INF7-K(GalNAc)2, only induced leakage of cholesterol-poor liposomes. Given that endosomal membranes of eukaryotic cells contain <5% cholesterol, this implies that the conjugate will display a higher selectivity toward endosomal membranes. Although both INF7 and INF7-K(GalNAc)2 were found to increase the transfection efficiency on polyplex-mediated gene transfer to parenchymal liver cells by 30-fold, only INF7-K(GalNAc)2appeared to do so in an ASGPr-specific manner. In mice, INF7-K(GalNAc)2 was specifically targeted to the liver, whereas INF7 was distributed evenly over various organs. In summary, we have prepared a nontoxic cell-specific lysosome disruptive element that improves gene delivery to parenchymal liver cells via the ASGPr. Its high cell specificity and preference to lyse intracellular membranes make this conjugate a promising lead in hepatocyte-specific drug/gene delivery protocols. The development of a viable nonviral gene delivery system continues to be an important theme in gene therapy (1Niidome T. Urakawa M. Sato H. Takahara Y. Anai T. Hatakayama T. Wada A. Hirayama T. Aoyagi H. Biomaterials. 2000; 21: 1811-1819Crossref PubMed Scopus (50) Google Scholar). The packaging of DNA into compact particles, the cellular uptake, the endosomal escape, and unpacking of these particles as well as the subsequent transfer of DNA to the nucleus are considered important steps in this regard (2Kichler A. Mechtler K. Behr J.P. Wagner E. Bioconj. Chem. 1997; 8: 213-221Crossref PubMed Scopus (89) Google Scholar). A number of DNA-packaging compounds have been reported, including cationic lipids, polymers and/or peptides that were designed to self-assemble with DNA to form intermolecular complexes (3Simoes S. Slepushkin V. Pires P. Gaspar R. de Lima M.C.P. Duzgunes N. Gene Ther. 1999; 65: 1798-1807Crossref Scopus (162) Google Scholar, 4Watabe A. Yamaguchi T. Kawanishi T. Uchida E. Eguchi A. Mizuguchi H. Mayumi T. Nakanishi M. Hayakawa T. Biochim. Biophys. Acta Biomembr. 1999; 12: 1-2Google Scholar, 5Zanta M.A. Belguise Valladier P. Behr J.P. Proc. Natl. Acad. Sci. U. S. A. 1999; 96: 91-96Crossref PubMed Scopus (669) Google Scholar, 6Lim D.W. Yeom Y.I. Park T.G. Bioconj. Chem. 2000; 11: 688-695Crossref PubMed Scopus (84) Google Scholar, 7Morris M.C. Vidal P. Chaloin L. Heitz F. Divita G. Nucleic Acids Res. 1997; 25: 2730-2736Crossref PubMed Scopus (458) Google Scholar, 8Torchilin V.P. Rammohan R. Weissig V. Levchenko T.S. Proc. Natl. Acad. Sci. U. S. A. 2001; 98: 8786-8791Crossref PubMed Scopus (700) Google Scholar). Upon internalization, the packaged DNA is transported to the lysosome, which subsequently degrades its content, making lysosomal escape a key step in gene delivery. To facilitate the intracellular transport of the packaged DNA to the nucleus and thus to enhance the transfection capacity of the nonviral gene delivery vehicles, lysosome disruptive elements (LDEs) 1The abbreviations used for: LDE(s), lysosome disruptive element(s); ASGPr, asialoglycoprotein receptor; BHK, baby hamster kidney; Boc, t-butoxycarbonyl; BOP, benzotriazol-1-yloxy-tris(dimethylamino)phosphonium hexafluorophosphate; BSA, bovine serum albumin; CMV, cytomegalovirus; Fmoc, N-(9-fluorenyl)methoxycarbonyl; HA, hemagglutinin; HOBt, hydroxybenzotriazole; HPLC, high performance liquid chromatography; K(GalNAc)2, di-N α,N ε-(5-(2-acetamido-2-deoxy-β-d-galactopyranosyloxy)pentanomido) lysine; LC-MS, liquid chromatography-mass spectrometry; Luc, luciferase; MALDI, matrix-assisted laser desorption/ionization; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; TOF, time-of-flight. 1The abbreviations used for: LDE(s), lysosome disruptive element(s); ASGPr, asialoglycoprotein receptor; BHK, baby hamster kidney; Boc, t-butoxycarbonyl; BOP, benzotriazol-1-yloxy-tris(dimethylamino)phosphonium hexafluorophosphate; BSA, bovine serum albumin; CMV, cytomegalovirus; Fmoc, N-(9-fluorenyl)methoxycarbonyl; HA, hemagglutinin; HOBt, hydroxybenzotriazole; HPLC, high performance liquid chromatography; K(GalNAc)2, di-N α,N ε-(5-(2-acetamido-2-deoxy-β-d-galactopyranosyloxy)pentanomido) lysine; LC-MS, liquid chromatography-mass spectrometry; Luc, luciferase; MALDI, matrix-assisted laser desorption/ionization; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; TOF, time-of-flight. have been successfully applied, including amphipathic peptides (9Wolfert M.A. Seymour L.W. Gene Ther. 1998; 5: 409-414Crossref PubMed Scopus (92) Google Scholar, 10Gottschalk S. Sparrow J.T. Hauer J. Mims M.P. Leland F.E. Woo S.L.C. Smith L.C. Gene Ther. 1996; 3: 448-457PubMed Google Scholar, 11Wyman T.B. Nicol F. Zelphati 1997; PubMed Scopus Google Scholar, 1999; PubMed Scopus Google Scholar, N. J. Chem. 1996; PubMed Scopus Google Scholar, R. Bioconj. Chem. 1996; PubMed Scopus Google Scholar, K. M. R. Bioconj. Chem. PubMed Scopus Google Scholar, G. A. 1998; 8: PubMed Scopus Google of the amphipathic peptides are from elements that cellular and intracellular capacity generally on the and the Although are these peptides a into an amphipathic and into T.B. Nicol F. Zelphati 1997; PubMed Scopus Google Scholar, 1999; PubMed Scopus Google Scholar). the peptides with and/or endosomal the from and peptides and have been to to transfection of complexes in M.A. Seymour L.W. Gene Ther. 1998; 5: 409-414Crossref PubMed Scopus (92) Google Scholar, P. A. J. P. Gene Ther. 1999; PubMed Scopus Google Scholar). Although have the of on nonviral gene transfer A. M. R. J. M. Biochim. Biophys. Biomembr. 1998; PubMed Scopus Google Scholar, Mechtler K. Wagner E. J. Chem. PubMed Google Scholar, E. K. M. Proc. Natl. Acad. Sci. U. S. A. PubMed Scopus Google the of targeted which the cellular delivery of DNA and its to the is have that coupling of a to a to a higher uptake of by the cell D.W. Yeom Y.I. Park T.G. Bioconj. Chem. 2000; 11: 688-695Crossref PubMed Scopus (84) Google Scholar, Chem. 2001; 11: PubMed Scopus Google Scholar, L. A. J. Chem. 1999; PubMed Scopus Google Scholar, M. M. K. E. Y. M. Gene Ther. 2000; PubMed Scopus Google Scholar). The was to a targeted Two a peptide from HA, and JTS-1, an INF7 designed for were S. Sparrow J.T. Hauer J. Mims M.P. Leland F.E. Woo S.L.C. Smith L.C. Gene Ther. 1996; 3: 448-457PubMed Google Scholar, L.C. J. V. Sparrow J.T. 1998; PubMed Scopus Google L. J.P. Biochim. Biophys. 2000; Scopus Google Scholar). the promising peptide in of and was with a for the asialoglycoprotein receptor (ASGPr), (1Niidome T. Urakawa M. Sato H. Takahara Y. Anai T. Hatakayama T. Wada A. Hirayama T. Aoyagi H. Biomaterials. 2000; 21: 1811-1819Crossref PubMed Scopus (50) Google M.A. Seymour L.W. Gene Ther. 1998; 5: 409-414Crossref PubMed Scopus (92) Google Scholar, Chem. 2001; 11: PubMed Scopus Google Scholar, L. A. J. Chem. 1999; PubMed Scopus Google Scholar, M. M. K. E. Y. M. Gene Ther. 2000; PubMed Scopus Google Scholar, 1997; Scopus Google on parenchymal liver this we that the INF7-K(GalNAc)2, a high affinity for the and high in cholesterol-poor making for targeted in parenchymal cells. INF7-K(GalNAc)2, the in the liver in and improves the transfer of to parenchymal liver cells in an of this study was to nonviral gene delivery by the of targeted a step we have tested and for their lysosome disruptive capacity in S. Sparrow J.T. Hauer J. Mims M.P. Leland F.E. Woo S.L.C. Smith L.C. Gene Ther. 1996; 3: 448-457PubMed Google Scholar). INF7 was found to a rapid and cholesterol-independent leakage of liposomes, whereas leakage was and was to disrupt cholesterol-poor with the of S. Sparrow J.T. Hauer J. Mims M.P. Leland F.E. Woo S.L.C. Smith L.C. Gene Ther. 1996; 3: 448-457PubMed Google leakage of cholesterol-poor by INF7 with only leakage by The of and INF7 is the of in of the peptides the peptides are in that INF7 and have a in membranes 1999; PubMed Scopus Google Scholar, A. 1998; PubMed Scopus Google Scholar, J. A. 1999; PubMed Scopus Google Scholar, J. A. J. 1999; PubMed Scopus Google Scholar, A. J. Chem. 2000; PubMed Scopus Google Scholar). will be to this the the promising was with a to the peptide for parenchymal liver cells. a we used K(GalNAc)2, which was to be to liposomes, and to liver parenchymal cells 1997; Scopus Google Scholar, L. A. E. J. Chem. 2001; PubMed Scopus Google Scholar, P. E. H. Bioconj. Chem. PubMed Scopus Google Scholar). The conjugate to be the parent peptide μm). the of the conjugate was in that only disrupted cholesterol-poor liposomes. be an as INF7 is designed to specifically on the lysosomal membranes of cells. by be the of the that leakage on the content, in contrast to INF7 disruptive peptides facilitate and a of the S. PubMed Scopus Google Scholar). The of INF7 and its that INF7 membranes via both of which in cholesterol-rich membranes and is by the of the the of leakage of from INF7 to as the of for both INF7 and the of the with the ability of the peptide to form the of INF7-K(GalNAc)2 in cholesterol-rich the by INF7-K(GalNAc)2 by of the To this the and of the peptides in the to be peptide was designed for delivery. INF7 to the with an affinity of which is have that an affinity of for the be for of INF7-K(GalNAc)2 L. A. E. J. Chem. 2001; PubMed Scopus Google Scholar, H. K. J. J. 1999; 3: Google of this study was to a targeted for nonviral gene To this we have the of the peptides on the gene transfer efficiency of an nonviral gene delivery on the cationic peptide in parenchymal liver cells S. Sparrow J.T. Hauer J. Mims M.P. Leland F.E. Woo S.L.C. Smith L.C. Gene Ther. 1996; 3: 448-457PubMed Google Scholar). DNA with be for the generally are and and are J. Res. 1999; PubMed Scopus Google Scholar, Bioconj. Chem. 1997; 8: PubMed Scopus Google Scholar). and INF7-K(GalNAc)2 to a 30-fold, increase in the transfection efficiency of complexes in parenchymal cells. was in the leakage INF7-K(GalNAc)2 to be the is for by the uptake of the targeted by parenchymal liver cells. be in that and cellular are of INF7-K(GalNAc)2 was in the of which uptake, whereas on the transfection INF7-K(GalNAc)2 the transfection in whereas INF7 and were in and parenchymal cells. that the of INF7 is by the and will have In with parenchymal liver cells are to cell the transfection in cells was found to be higher in parenchymal cells Gene Ther. 2000; PubMed Scopus Google that INF7-K(GalNAc)2 was in cells that uptake and the of INF7-K(GalNAc)2 are with of INF7 leakage that the is we that this is the the of INF7-K(GalNAc)2 in cells. The of of INF7 and INF7 and be into the with the the peptides have only a is that be by uptake of the cationic in the of receptor the receptor and V. J. 2000; PubMed Scopus Google as INF7-K(GalNAc)2, on the be by with the and subsequently uptake via an INF7-K(GalNAc)2 will escape of the DNA from the lysosomal been that lysosome leakage and lead to intracellular of including and Although these are with a leakage of these in the of the cell Y. 2001; 8: PubMed Scopus Google Scholar). that the peptides are in parenchymal liver important in regard of in the of INF7 and its The in that by the liver, whereas INF7 is distributed evenly over various organs. In liver uptake of the is higher that of that we have a hepatocyte-specific for in we a targeted INF7-K(GalNAc)2, which lysosomal escape in a fashion. Its and the that INF7-K(GalNAc)2 be to the transfection of nonviral gene transfer vehicles M. M. K. E. Y. M. Gene Ther. 2000; PubMed Scopus Google and of for H. K. J. J. 1999; 3: Google Scholar, P. E. H. Bioconj. Chem. PubMed Scopus Google Scholar, M. N. J. Chem. 1996; PubMed Scopus Google by the escape from the lysosomal which to be a in both S. A. M. M. J. P. 2000; PubMed Scopus Google Scholar). only gene that in the lysosomal from of targeted The development of a viable nonviral gene delivery system continues to be an important theme in gene therapy (1Niidome T. Urakawa M. Sato H. Takahara Y. Anai T. Hatakayama T. Wada A. Hirayama T. Aoyagi H. Biomaterials. 2000; 21: 1811-1819Crossref PubMed Scopus (50) Google Scholar). The packaging of DNA into compact particles, the cellular uptake, the endosomal escape, and unpacking of these particles as well as the subsequent transfer of DNA to the nucleus are considered important steps in this regard (2Kichler A. Mechtler K. Behr J.P. Wagner E. Bioconj. Chem. 1997; 8: 213-221Crossref PubMed Scopus (89) Google Scholar). A number of DNA-packaging compounds have been reported, including cationic lipids, polymers and/or peptides that were designed to self-assemble with DNA to form intermolecular complexes (3Simoes S. Slepushkin V. Pires P. Gaspar R. de Lima M.C.P. Duzgunes N. Gene Ther. 1999; 65: 1798-1807Crossref Scopus (162) Google Scholar, 4Watabe A. Yamaguchi T. Kawanishi T. Uchida E. Eguchi A. Mizuguchi H. Mayumi T. Nakanishi M. Hayakawa T. Biochim. Biophys. Acta Biomembr. 1999; 12: 1-2Google Scholar, 5Zanta M.A. Belguise Valladier P. Behr J.P. Proc. Natl. Acad. Sci. U. S. A. 1999; 96: 91-96Crossref PubMed Scopus (669) Google Scholar, 6Lim D.W. Yeom Y.I. Park T.G. Bioconj. Chem. 2000; 11: 688-695Crossref PubMed Scopus (84) Google Scholar, 7Morris M.C. Vidal P. Chaloin L. Heitz F. Divita G. Nucleic Acids Res. 1997; 25: 2730-2736Crossref PubMed Scopus (458) Google Scholar, 8Torchilin V.P. Rammohan R. Weissig V. Levchenko T.S. Proc. Natl. Acad. Sci. U. S. A. 2001; 98: 8786-8791Crossref PubMed Scopus (700) Google Scholar). Upon internalization, the packaged DNA is transported to the lysosome, which subsequently degrades its content, making lysosomal escape a key step in gene delivery. To facilitate the intracellular transport of the packaged DNA to the nucleus and thus to enhance the transfection capacity of the nonviral gene delivery vehicles, lysosome disruptive elements (LDEs) 1The abbreviations used for: LDE(s), lysosome disruptive element(s); ASGPr, asialoglycoprotein receptor; BHK, baby hamster kidney; Boc, t-butoxycarbonyl; BOP, benzotriazol-1-yloxy-tris(dimethylamino)phosphonium hexafluorophosphate; BSA, bovine serum albumin; CMV, cytomegalovirus; Fmoc, N-(9-fluorenyl)methoxycarbonyl; HA, hemagglutinin; HOBt, hydroxybenzotriazole; HPLC, high performance liquid chromatography; K(GalNAc)2, di-N α,N ε-(5-(2-acetamido-2-deoxy-β-d-galactopyranosyloxy)pentanomido) lysine; LC-MS, liquid chromatography-mass spectrometry; Luc, luciferase; MALDI, matrix-assisted laser desorption/ionization; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; TOF, time-of-flight. 1The abbreviations used for: LDE(s), lysosome disruptive element(s); ASGPr, asialoglycoprotein receptor; BHK, baby hamster kidney; Boc, t-butoxycarbonyl; BOP, benzotriazol-1-yloxy-tris(dimethylamino)phosphonium hexafluorophosphate; BSA, bovine serum albumin; CMV, cytomegalovirus; Fmoc, N-(9-fluorenyl)methoxycarbonyl; HA, hemagglutinin; HOBt, hydroxybenzotriazole; HPLC, high performance liquid chromatography; K(GalNAc)2, di-N α,N ε-(5-(2-acetamido-2-deoxy-β-d-galactopyranosyloxy)pentanomido) lysine; LC-MS, liquid chromatography-mass spectrometry; Luc, luciferase; MALDI, matrix-assisted laser desorption/ionization; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; TOF, time-of-flight. have been successfully applied, including amphipathic peptides (9Wolfert M.A. Seymour L.W. Gene Ther. 1998; 5: 409-414Crossref PubMed Scopus (92) Google Scholar, 10Gottschalk S. Sparrow J.T. Hauer J. Mims M.P. Leland F.E. Woo S.L.C. Smith L.C. Gene Ther. 1996; 3: 448-457PubMed Google Scholar, 11Wyman T.B. Nicol F. Zelphati 1997; PubMed Scopus Google Scholar, 1999; PubMed Scopus Google Scholar, N. J. Chem. 1996; PubMed Scopus Google Scholar, R. Bioconj. Chem. 1996; PubMed Scopus Google Scholar, K. M. R. Bioconj. Chem. PubMed Scopus Google Scholar, G. A. 1998; 8: PubMed Scopus Google Scholar). The of the amphipathic peptides are from elements that cellular and intracellular capacity generally on the and the Although are these peptides a into an amphipathic and into T.B. Nicol F. Zelphati 1997; PubMed Scopus Google Scholar, 1999; PubMed Scopus Google Scholar). the peptides with and/or endosomal the from and peptides and have been to to transfection of complexes in M.A. Seymour L.W. Gene Ther. 1998; 5: 409-414Crossref PubMed Scopus (92) Google Scholar, P. A. J. P. Gene Ther. 1999; PubMed Scopus Google Scholar). Although have the of on nonviral gene transfer A. M. R. J. M. Biochim. Biophys. Biomembr. 1998; PubMed Scopus Google Scholar, Mechtler K. Wagner E. J. Chem. PubMed Google Scholar, E. K. M. Proc. Natl. Acad. Sci. U. S. A. PubMed Scopus Google the of targeted which the cellular delivery of DNA and its to the is have that coupling of a to a to a higher uptake of by the cell D.W. Yeom Y.I. Park T.G. Bioconj. Chem. 2000; 11: 688-695Crossref PubMed Scopus (84) Google Scholar, Chem. 2001; 11: PubMed Scopus Google Scholar, L. A. J. Chem. 1999; PubMed Scopus Google Scholar, M. M. K. E. Y. M. Gene Ther. 2000; PubMed Scopus Google Scholar). The was to a targeted Two a peptide from HA, and JTS-1, an INF7 designed for were S. Sparrow J.T. Hauer J. Mims M.P. Leland F.E. Woo S.L.C. Smith L.C. Gene Ther. 1996; 3: 448-457PubMed Google Scholar, L.C. J. V. Sparrow J.T. 1998; PubMed Scopus Google L. J.P. Biochim. Biophys. 2000; Scopus Google Scholar). the promising peptide in of and was with a for the asialoglycoprotein receptor (ASGPr), (1Niidome T. Urakawa M. Sato H. Takahara Y. Anai T. Hatakayama T. Wada A. Hirayama T. Aoyagi H. Biomaterials. 2000; 21: 1811-1819Crossref PubMed Scopus (50) Google M.A. Seymour L.W. Gene Ther. 1998; 5: 409-414Crossref PubMed Scopus (92) Google Scholar, Chem. 2001; 11: PubMed Scopus Google Scholar, L. A. J. Chem. 1999; PubMed Scopus Google Scholar, M. M. K. E. Y. M. Gene Ther. 2000; PubMed Scopus Google Scholar, 1997; Scopus Google on parenchymal liver cells. In this we that the INF7-K(GalNAc)2, a high affinity for the and high in cholesterol-poor making for targeted in parenchymal cells. INF7-K(GalNAc)2, the in the liver in and improves the transfer of to parenchymal liver cells in an fashion. of this study was to nonviral gene delivery by the of targeted a step we have tested and for their lysosome disruptive capacity in S. Sparrow J.T. Hauer J. Mims M.P. Leland F.E. Woo S.L.C. Smith L.C. Gene Ther. 1996; 3: 448-457PubMed Google Scholar). INF7 was found to a rapid and cholesterol-independent leakage of liposomes, whereas leakage was and was to disrupt cholesterol-poor with the of S. Sparrow J.T. Hauer J. Mims M.P. Leland F.E. Woo S.L.C. Smith L.C. Gene Ther. 1996; 3: 448-457PubMed Google leakage of cholesterol-poor by INF7 with only leakage by The of and INF7 is the of in of the peptides the peptides are in that INF7 and have a in membranes 1999; PubMed Scopus Google Scholar, A. 1998; PubMed Scopus Google Scholar, J. A. 1999; PubMed Scopus Google Scholar, J. A. J. 1999; PubMed Scopus Google Scholar, A. J. Chem. 2000; PubMed Scopus Google Scholar). will be to this the the promising was with a to the peptide for parenchymal liver cells. a we used K(GalNAc)2, which was to be to liposomes, and to liver parenchymal cells 1997; Scopus Google Scholar, L. A. E. J. Chem. 2001; PubMed Scopus Google Scholar, P. E. H. Bioconj. Chem. PubMed Scopus Google Scholar). The conjugate to be the parent peptide μm). the of the conjugate was in that only disrupted cholesterol-poor liposomes. be an as INF7 is designed to specifically on the lysosomal membranes of cells. by be the of the that leakage on the content, in contrast to INF7 disruptive peptides facilitate and a of the S. PubMed Scopus Google Scholar). The of INF7 and its that INF7 membranes via both of which in cholesterol-rich membranes and is by the of the the of leakage of from INF7 to as the of for both INF7 and the of the with the ability of the peptide to form the of INF7-K(GalNAc)2 in cholesterol-rich the by INF7-K(GalNAc)2 by of the To this the and of the peptides in the to be peptide was designed for delivery. INF7 to the with an affinity of which is have that an affinity of for the be for of INF7-K(GalNAc)2 L. A. E. J. Chem. 2001; PubMed Scopus Google Scholar, H. K. J. J. 1999; 3: Google of this study was to a targeted for nonviral gene To this we have the of the peptides on the gene transfer efficiency of an nonviral gene delivery on the cationic peptide in parenchymal liver cells S. Sparrow J.T. Hauer J. Mims M.P. Leland F.E. Woo S.L.C. Smith L.C. Gene Ther. 1996; 3: 448-457PubMed Google Scholar). DNA with be for the generally are and and are J. Res. 1999; PubMed Scopus Google Scholar, Bioconj. Chem. 1997; 8: PubMed Scopus Google Scholar). and INF7-K(GalNAc)2 to a 30-fold, increase in the transfection efficiency of complexes in parenchymal cells. was in the leakage INF7-K(GalNAc)2 to be the is for by the uptake of the targeted by parenchymal liver cells. be in that and cellular are of INF7-K(GalNAc)2 was in the of which uptake, whereas on the transfection INF7-K(GalNAc)2 the transfection in whereas INF7 and were in and parenchymal cells. that the of INF7 is by the and will have In with parenchymal liver cells are to cell the transfection in cells was found to be higher in parenchymal cells Gene Ther. 2000; PubMed Scopus Google that INF7-K(GalNAc)2 was in cells that uptake and the of INF7-K(GalNAc)2 are with of INF7 leakage that the is we that this is the the of INF7-K(GalNAc)2 in cells. The of of INF7 and INF7 and be into the with the the peptides have only a is that be by uptake of the cationic in the of receptor the receptor and V. J. 2000; PubMed Scopus Google as INF7-K(GalNAc)2, on the be by with the and subsequently uptake via an INF7-K(GalNAc)2 will escape of the DNA from the lysosomal been that lysosome leakage and lead to intracellular of including and Although these are with a leakage of these in the of the cell Y. 2001; 8: PubMed Scopus Google Scholar). that the peptides are in parenchymal liver important in regard of in the of INF7 and its The in that by the liver, whereas INF7 is distributed evenly over various organs. In liver uptake of the is higher that of that we have a hepatocyte-specific for in we a targeted INF7-K(GalNAc)2, which lysosomal escape in a fashion. Its and the that INF7-K(GalNAc)2 be to the transfection of nonviral gene transfer vehicles M. M. K. E. Y. M. Gene Ther. 2000; PubMed Scopus Google and of for H. K. J. J. 1999; 3: Google Scholar, P. E. H. Bioconj. Chem. PubMed Scopus Google Scholar, M. N. J. Chem. 1996; PubMed Scopus Google by the escape from the lysosomal which to be a in both S. A. M. M. J. P. 2000; PubMed Scopus Google Scholar). only gene that in the lysosomal from of targeted The of this study was to nonviral gene delivery by the of targeted a step we have tested and for their lysosome disruptive capacity in S. Sparrow J.T. Hauer J. Mims M.P. Leland F.E. Woo S.L.C. Smith L.C. Gene Ther. 1996; 3: 448-457PubMed Google Scholar). INF7 was found to a rapid and cholesterol-independent leakage of liposomes, whereas leakage was and was to disrupt cholesterol-poor with the of S. Sparrow J.T. Hauer J. Mims M.P. Leland F.E. Woo S.L.C. Smith L.C. Gene Ther. 1996; 3: 448-457PubMed Google leakage of cholesterol-poor by INF7 with only leakage by The of and INF7 is the of in of the peptides the peptides are in that INF7 and have a in membranes 1999; PubMed Scopus Google Scholar, A. 1998; PubMed Scopus Google Scholar, J. A. 1999; PubMed Scopus Google Scholar, J. A. J. 1999; PubMed Scopus Google Scholar, A. J. Chem. 2000; PubMed Scopus Google Scholar). will be to this In the the promising was with a to the peptide for parenchymal liver cells. a we used K(GalNAc)2, which was to be to liposomes, and to liver parenchymal cells 1997; Scopus Google Scholar, L. A. E. J. Chem. 2001; PubMed Scopus Google Scholar, P. E. H. Bioconj. Chem. PubMed Scopus Google Scholar). The conjugate to be the parent peptide μm). the of the conjugate was in that only disrupted cholesterol-poor liposomes. be an as INF7 is designed to specifically on the lysosomal membranes of cells. by be the of the The that leakage on the content, in contrast to INF7 disruptive peptides facilitate and a of the S. PubMed Scopus Google Scholar). The of INF7 and its that INF7 membranes via both of which in cholesterol-rich membranes and is by the of the the of leakage of from INF7 to as the of for both INF7 and the of the with the ability of the peptide to form the of INF7-K(GalNAc)2 in cholesterol-rich the by INF7-K(GalNAc)2 by of the To this the and of the peptides in the to be The peptide was designed for delivery. INF7 to the with an affinity of which is have that an affinity of for the be for of INF7-K(GalNAc)2 L. A. E. J. Chem. 2001; PubMed Scopus Google Scholar, H. K. J. J. 1999; 3: Google Scholar). The of this study was to a targeted for nonviral gene To this we have the of the peptides on the gene transfer efficiency of an nonviral gene delivery on the cationic peptide in parenchymal liver cells S. Sparrow J.T. Hauer J. Mims M.P. Leland F.E. Woo S.L.C. Smith L.C. Gene Ther. 1996; 3: 448-457PubMed Google Scholar). DNA with be for the generally are and and are J. Res. 1999; PubMed Scopus Google Scholar, Bioconj. Chem. 1997; 8: PubMed Scopus Google Scholar). and INF7-K(GalNAc)2 to a 30-fold, increase in the transfection efficiency of complexes in parenchymal cells. was in the leakage INF7-K(GalNAc)2 to be the is for by the uptake of the targeted by parenchymal liver cells. be in that and cellular are The of INF7-K(GalNAc)2 was in the of which uptake, whereas on the transfection INF7-K(GalNAc)2 the transfection in whereas INF7 and were in and parenchymal cells. that the of INF7 is by the and will have In with parenchymal liver cells are to cell the transfection in cells was found to be higher in parenchymal cells Gene Ther. 2000; PubMed Scopus Google Scholar). The that INF7-K(GalNAc)2 was in cells that uptake and the of INF7-K(GalNAc)2 are with of INF7 leakage that the is we that this is the the of INF7-K(GalNAc)2 in cells. The of of INF7 and INF7 and be into the with the the peptides have only a is that be by uptake of the cationic in the of receptor the receptor and V. J. 2000; PubMed Scopus Google as INF7-K(GalNAc)2, on the be by with the and subsequently uptake via an INF7-K(GalNAc)2 will escape of the DNA from the lysosomal been that lysosome leakage and lead to intracellular of including and Although these are with a leakage of these in the of the cell Y. 2001; 8: PubMed Scopus Google Scholar). that the peptides are in parenchymal liver cells. important in regard of in the of INF7 and its The in that by the liver, whereas INF7 is distributed evenly over various organs. In liver uptake of the is higher that of that we have a hepatocyte-specific for in In we a targeted INF7-K(GalNAc)2, which lysosomal escape in a fashion. Its and the that INF7-K(GalNAc)2 be to the transfection of nonviral gene transfer vehicles M. M. K. E. Y. M. Gene Ther. 2000; PubMed Scopus Google and of for H. K. J. J. 1999; 3: Google Scholar, P. E. H. Bioconj. Chem. PubMed Scopus Google Scholar, M. N. J. Chem. 1996; PubMed Scopus Google by the escape from the lysosomal which to be a in both S. A. M. M. J. P. 2000; PubMed Scopus Google Scholar). only gene that in the lysosomal from of targeted
42
Efficient Trace-labelling of Proteins with Iodine
A. S. McFarlane · Nature · 1958 · 2.6K citations
J. B. Gurdon · Trends in Biochemical Sciences · 1983 · 835 citations
Vladimir P. Torchilin, Ram Rammohan, Volkmar Weissig et al. · Proceedings of the National Academy of Sciences · 2001 · 779 citations · Full text